Duodenoscope contamination rates higher than expected, says FDA

Mackenzie Bean - Print  | 

Duodenoscopes contain higher levels of contamination than expected after reprocessing, the FDA said in an April 12 safety communication.

In October 2015, the FDA ordered Fujifilm Medical Systems, Olympus Medical Systems Corp., and Pentax of America to conduct postmarket surveillance studies to discover how well their duodenoscopes are reprocessed in real-world settings.

"The preliminary results as of March 2019 indicate higher than expected levels of contamination," the agency said.

The agency found that reports of infections linked to duodenoscopes peaked in 2015 at 250 reports before decreasing to under 100 reports in 2017.

However, the agency identified 45 infections linked to the devices and 159 reports of device contamination between Oct. 15, 2018, and March 31.

"These reports indicate that although the number of reports has declined, there continues to be a need for improvement of the safety of reprocessed duodenoscopes," the FDA said.

More articles on clinical leadership and infection control:

Teamwork among top 3 drivers of nurse engagement, survey shows
Report: Veteran's leg amputated after VA fails to log home care appointments
ICU healthcare workers have low hand hygiene compliance, study finds

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.